[go: up one dir, main page]

WO2013058681A3 - Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof - Google Patents

Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof Download PDF

Info

Publication number
WO2013058681A3
WO2013058681A3 PCT/RU2012/000830 RU2012000830W WO2013058681A3 WO 2013058681 A3 WO2013058681 A3 WO 2013058681A3 RU 2012000830 W RU2012000830 W RU 2012000830W WO 2013058681 A3 WO2013058681 A3 WO 2013058681A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
hydrogen
membered
dioxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2012/000830
Other languages
French (fr)
Russian (ru)
Other versions
WO2013058681A2 (en
Inventor
Александр Васильевич ИВАЩЕНКО
Олег Дмитриевич МИТЬКИН
Мадина Георгиевна КАДИЕВА
Илья Матусович ОКУНЬ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEWVAC LLC
Original Assignee
NEWVAC LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEWVAC LLC filed Critical NEWVAC LLC
Publication of WO2013058681A2 publication Critical patent/WO2013058681A2/en
Publication of WO2013058681A3 publication Critical patent/WO2013058681A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to novel compounds of general formula 1, namely substituted phenoxyacetic acids and esters and amides thereof, which comprise a 2,6-dioxo-2,3,6,7-tetrahydro-1H-purine-8-yl fragment and exhibit antagonist activity against A2A adenosine receptors, and to the use thereof as a therapeutic principle and agent (adjuvant) for pharmaceutical compositions and drugs, as well as to methods for treating diseases of the central nervous system, oncological diseases and viral and bacterial diseases, where R1, R2 and R3, not necessarily simultaneously, are hydrogen, C1-C5 alkyl, C3-C5 alkenyl or C3-C5 alkynyl; R4 is hydrogen, a halogen atom, a hydroxyl, C1-С3 alkyl, C1-С3 alkyloxy; R5 is hydrogen, C1-C3 alkyl, the group -C(O)R6; and R6 is a hydroxyl, C1-С5 alkyloxy, С3-С5 alkenyloxy, С3-С5 alkynyloxy, an optionally substituted amino group where the substitutes, not necessarily identical, are selected from hydrogen, C1-C5 alkyl optionally substituted with a mono- or dialkylamino group or an alkoxy group or a 5-6 membered saturated heterocyclyl comprising 1-2 heteroatoms selected from nitrogen and oxygen; pyridyl or phenyl optionally substituted with 1-3 methoxy groups; or an optionally substituted 6 membered saturated heterocyclyl optionally annulated with a 5 membered unsaturated heterocyclyl and comprising 2 nitrogen atoms, where the substitutes are selected from С1-С5 alkyl optionally substituted with a 5 membered heteroaryl comprising 1-3 heteroatoms selected from nitrogen and oxygen; or a 6 membered optionally saturated heterocyclyl comprising 1-2 nitrogen atoms optionally substituted with C1-C5 alkyl, oxo, optionally substituted with phenyl; and the broken line with an adjacent unbroken line represents a single, double or triple bond.
PCT/RU2012/000830 2011-10-18 2012-10-12 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof Ceased WO2013058681A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011141962/04A RU2477726C1 (en) 2011-10-18 2011-10-18 Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof
RU2011141962 2011-10-18

Publications (2)

Publication Number Publication Date
WO2013058681A2 WO2013058681A2 (en) 2013-04-25
WO2013058681A3 true WO2013058681A3 (en) 2013-06-20

Family

ID=48141584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2012/000830 Ceased WO2013058681A2 (en) 2011-10-18 2012-10-12 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof

Country Status (2)

Country Link
RU (1) RU2477726C1 (en)
WO (1) WO2013058681A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
WO2021093701A1 (en) * 2019-11-11 2021-05-20 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111018856B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-Substituted styryl xanthine derivatives and uses thereof
CN111072663B (en) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-Substituted styryl xanthine derivatives and uses thereof
EP4118083A4 (en) * 2020-03-10 2024-07-03 Marvel Biotechnology Purine compounds for treating disorders
WO2022174351A1 (en) * 2021-02-19 2022-08-25 Marvel Biotechnology Purine compounds for treating disorders
US20250353849A1 (en) * 2021-12-03 2025-11-20 Marvel Biotechnology Purine compounds for treating disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559893A1 (en) * 1990-10-18 1993-09-15 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
EP0590919A1 (en) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for parkinson's disease
EP0628311A1 (en) * 1992-07-08 1994-12-14 Kyowa Hakko Kogyo Co., Ltd. Antidepressant
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200701484B (en) * 2004-08-03 2008-07-30 Biorexis Pharmaceutical Corp Combination therapy using transferrin fusion proteins comprising GLP-1
EP1838298A4 (en) * 2004-12-17 2009-03-04 Univ Pennsylvania STILBENE DERIVATIVES AND THEIR USE FOR FIXING AND IMAGING AMYLOID PLATES
CN102137836B (en) * 2008-07-28 2015-08-26 赛丹思科大学 Compounds for the Treatment of Metabolic Diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559893A1 (en) * 1990-10-18 1993-09-15 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
EP0628311A1 (en) * 1992-07-08 1994-12-14 Kyowa Hakko Kogyo Co., Ltd. Antidepressant
EP0590919A1 (en) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agents for parkinson's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBMED accession no. 4663020 *
KASE H. ET AL.: "Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease", NEUROLOGY, vol. 61, no. 11 SUP, 2003, pages 97 - 100 *

Also Published As

Publication number Publication date
RU2477726C1 (en) 2013-03-20
WO2013058681A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
WO2013058681A3 (en) Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof
EA201591204A3 (en) NEW CHIRAL N-ACYL-5,6,7, (8-SUBSTITUTED) -TETRAHYDRO- [1,2,4] TRIAZOLO [4,3-A] PIRASINS AS SELECTIVE ANTAGONISTS OF NK-3 RECEPTOR, PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL COMPOSITION NK-3, PHARMACEUTICAL COMPOSITION ANTAGONISTS, PHARMACEUTICAL COMPOSITION NK-3 NON-MEDIATED DISORDERS NK-3 RECEPTORS AND THEIR CHIRAL SYNTHESIS
SA518391518B1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
NO20091741L (en) Pyrazoline Compounds as Mineral Corticoid Receptor Antagonists
NO20064065L (en) Diaminopyrimidines such as P2X3 and P2X2 / 3 antagonists
AR040351A1 (en) DERIVATIVES OF QUINUCLIDINE-AMIDA, PHARMACEUTICAL COMPOSITION, COMPOSITE PREPARATION PROCEDURE AND ITS USE TO MANUFACTURE OF MEDICINES
NO20071660L (en) Novel pyridinone derivatives and their use as positive allosteric modulators of MGLUR2 receptors
DE602008005771D1 (en) DISUBSTITUTED ALKYL-8-AZABICYCLOÄ3.2.1ÜOKTAN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
NO20072371L (en) Kinuclidine derivatives and their use as muscarinic M3 receptor antagonists
MY145633A (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
NZ603643A (en) Purinone derivative
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX390264B (en) D2 ANTAGONISTS, SYNTHESIS METHODS AND METHODS OF USE.
WO2007084914A3 (en) Phenoxy-substituted pyrimidines as adenosine receptor antagonists
NO20076060L (en) Piperidin-4-yl amide derivatives and their use as SST receptor subtype 5 antagonists
NO20092689L (en) Quinuclidinol derivatives as muscarinic receptor antagonists
RU2014121205A (en) ASOLES DERIVATIVES
MX2010002171A (en) 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists.
MX349156B (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor.
PH12014500775A1 (en) Ethynyl derivatives as mglur5 allosteric modulators
EA201290582A1 (en) LIGANDS OF NEURAL NICOTIN ACETYL CHOLINE RECEPTOR αβ
EA201270421A1 (en) 1,2-DIHYDRO-2-OXOHINOLINE COMPOUNDS AS LIGANDS OF 5-NT RECEPTOR
MX2013006768A (en) Glucagon receptor modulators.
EA200870591A1 (en) 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR APPLICATION AS THE NICOTINE RECEPTOR OF ACETYLCHOLINE AS LIGANDS
AR068111A1 (en) COMPOSITE PIRAZINA AND PIPERIDIN REPLACED PIPERAZINIL, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A MEDICINAL PRODUCT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12842503

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12842503

Country of ref document: EP

Kind code of ref document: A2